JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, Ceresa D, Colombo M, Vigo T, Cigolini B, Rivoli G, Dragani M, Solimano I, Garuti A, Bellodi A, Ballestrero A, Ferrando L, Zoppoli G
У данной статьи нет абстракта.
British journal of haematology, 2025-01-18